Museveni applauds Dr. Magoola for securing U.S Patent for Cancer treatment
Abstract: MicroRNAs (miRNAs) maintain cellular homeostasis by blocking mRNAs by binding with them to fine-tune the expression of genes across...
Dei BioPharma is building Africa’s largest state-of-the-art pharmaceutical and biotech facility, pioneering the future of medicine with cutting-edge RNA technology and high-quality vaccines.
Our facility adheres to stringent US FDA, EU EMA, and WHO GMP standards, ensuring life-saving medicines and vaccines reach those who need them most.
We are set to launch across Africa, Europe, and the US, revolutionizing pharmaceutical accessibility with innovative solutions and global partnerships.
Dei BioPharma is at the forefront of revolutionizing African healthcare by pioneering biotech and pharmaceutical advancements. With a cutting-edge facility and a commitment to innovation, we aim to make high-quality medicines and vaccines accessible across the continent and beyond.
Dei Biopharma specializes in developing and manufacturing innovative medicines and vaccines. It was commissioned on July 6, 2021, by President Yoweri Museveni and Kenya President William Ruto (then Vice President).
As a leader in biologics, we produce safe and cost-effective alternatives to traditional therapies.
We address critical therapeutic areas, including infectious diseases, cancer, and chronic conditions, and we produce generics and nutraceuticals.
We innovate vaccines to reduce the threat of diseases.
We leverage cutting-edge research and world-class manufacturing to develop innovative pharmaceutical solutions.
While we are breaking ground as the first African biopharma company to enter Europe, the USA, and other developed markets, we remain committed to creating an impact in Africa and Uganda by creating jobs, pushing for sustainability, boosting healthcare access with affordable medicines, and growing talent through education and training programs.
This plant meets the world standards, at least the first bits that I have seen…. Local production is one of the ways of solving the problem of fake drugs so that the population consumes the right medicine.
Dei Biopharma Ltd is different from other foreign biotechnology companies such as Moderna that are being hosted by African countries.
Our leadership team combines decades of pharmaceuticals, biotechnology, and global healthcare expertise. Together, they lead DEI BioPharma in its mission to redefine healthcare for the better
Managing Director
Executive Director
Chief Executive Officer
Head of Human Capital
Dei Biopharma is always open to collaborations, partnerships, and inquiries. Whether you’re a healthcare provider, researcher, or global partner, we’d love to hear from you.
Mattuga, Wakiso District, Uganda
+256 000 0000
Abstract: MicroRNAs (miRNAs) maintain cellular homeostasis by blocking mRNAs by binding with them to fine-tune the expression of genes across...
Dr. Matthias Magoola Recognized at International Molecular Biologist Awards for Vaccine Research KAMPALA – Recognition for Groundbreaking Work in mRNA...
PUBLICATION BY DR. MATTHIAS MAGOOLA, CHEMIST Abstract MicroRNAs (miRNAs) play a crucial role in maintaining cellular homeostasis by binding to...